Trials / Recruiting
RecruitingNCT06819293
IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma
A Phase I, Open Label, Single Center Study Evaluating the Safety and Efficacy of IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Grit Biotechnology · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, single center, dose escalation, and dose extension IIT study aimed at evaluating the safety, efficacy, and pharmacokinetics of IB-T101 in adult patients with advanced clear renal cell carcinoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IB-T101 injection | IB-T101 injection to treat advanced clear renal cell carcinoma |
Timeline
- Start date
- 2024-12-06
- Primary completion
- 2027-12-07
- Completion
- 2027-12-07
- First posted
- 2025-02-11
- Last updated
- 2026-04-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06819293. Inclusion in this directory is not an endorsement.